1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

1/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系

基本信息

批准号：
10762157
负责人：
ERNEST MARTINEZ
金额：
$ 138.05万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10762157
关键词：
Address Affect African African American African American population American Award Bioinformatics Black race California Cancer Center Planning Grant Catchment Area Cell Line City of Hope Comprehensive Cancer Center Clinical Collaborations Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility County Crowding Disparity Drug Design Drug Targeting Economics Education Engineering Ensure Equity European FDA approved Faculty Fellowship Fostering Funding Goals Grant Growth Hispanic Americans Incubators Individual Infrastructure Institution Investments Joints Laboratories Latino Latino Population Los Angeles Malignant Neoplasms Master of Science Mentors Mentorship Minority Neighborhoods Not Hispanic or Latino Pharmaceutical Preparations Phase Physicians Population Population Heterogeneity Postdoctoral Fellow Prognosis Reporting Research Personnel Resources Scientist Section 8 Site Societies Students System Testing Therapeutic Agents Therapeutic Trials Toxic effect Training Training Programs Translations United States United States National Institutes of Health Universities Work anticancer research cancer health disparity clinical trial participant commercialization disparity elimination disparity reduction drug development drug discovery malignant breast neoplasm manufacturing facility medical schools men minority communities news next generation novel therapeutics phase 1 testing programs screening small molecule inhibitor success synergism therapeutic development women of color

项目摘要

The United States (U.S.) has led the world in drug discovery for over 50 years. While this is a significant accomplishment, U.S. drugs have been almost exclusively optimized and tested in non-Hispanic European- Americans and been minimally evaluated in men- or women-of-color. As a result, drugs that work well in non- Hispanic European-Americans (Anglos), may have unexpected toxicity or decreased efficacy in most of the world’s population. Disparities in U.S. drug development occur throughout the entire drug discovery pipeline. Only a small number of basic scientists are Latino/Hispanic- or African-American. Initial drug development and optimization takes place in cell lines derived from Anglos. Less than 2% of physicians conducting clinical trials are Latino/Hispanic- or African-American6. Most clinical trials participants are Anglos. Yet, new drugs are FDA approved for Latinos/Hispanics- and African-Americans/Africans without sufficient testing. It is unacceptable that drugs are developed by, and optimized for, only a fraction of our citizens. In this U54 partnership we aim to develop the resources, infrastructure, and training to mentor the next generation of researchers that reflect the diversity of our Catchment Area. Building on our successful P20 grant, here in this U54 partnership, UCR and CoHCCC aim to develop the collaborations, resources, and training programs to reduce disparities in drug development throughout the entire drug development pipeline. Our goal is for this program to become a focal point for UCR and CoHCCC to mentor and train a diverse force of cancer biologists and address the disparities in cancer therapeutics and drug development. Already, our P20 has fostered joint R01 grants, K01 grants, and pre-/post-doctoral fellowships. Both institutions are highly committed - CoHCCC contributed over $800K to our P20 grant and will contribute $250K/year to ensure the success of this U54 partnership. Aim 1 will strengthen UCR’s cancer research capacity and develop the resources to increase UCR/CoHCCC’s ability to jointly develop therapeutic agents optimized for the diverse populations in our catchment area. Aim 2 will increase the capacity of UCR and CoHCCC to jointly develop drugs that target disparities in survival affecting the diverse individuals living in our Southern California communities. Aim 3 will provide the training, opportunity, and mentorship to ensure that the next generation of therapeutic scientists and clinical trialists reflect the diversity of Southern California.

美国 (U.S.) 在药物发现方面领先世界 50 多年，这是一个重要的里程碑。成就，美国药物几乎完全在非西班牙裔欧洲人中进行了优化和测试美国人对有色人种男性或女性的评估很少，因此药物在非有色人种中效果良好。西班牙裔欧洲裔美国人（盎格鲁人）在大多数情况下可能会出现意想不到的毒性或疗效下降美国药物开发的差异存在于整个药物发现渠道中。只有少数基础科学家是拉丁裔/西班牙裔或非裔美国人。进行临床试验的医生中，只有不到 2% 的细胞系是在 Anglos 细胞系中进行优化的。大多数临床试验参与者是拉丁裔/西班牙裔或非裔美国人6。然而，新药是 FDA 批准的。在未经充分测试的情况下批准用于拉丁裔/西班牙裔和非裔美国人/非洲人是不可接受的。药物仅由我们的一小部分公民开发并优化。在这一 U54 合作伙伴关系中，我们的目标是：开发资源、基础设施和培训来指导下一代研究人员，以反映我们的集水区的多样性建立在我们成功的 P20 赠款的基础上，在这个 U54 合作伙伴关系中，UCR 和 CoHCCC 旨在开发合作、资源和培训计划，以减少药品方面的差异我们的目标是使该计划成为整个药物开发流程的焦点。 UCR 和 CoHCCC 的重点是指导和培训癌症生物学家的多元化力量并解决差异在癌症治疗和药物开发方面，我们的 P20 已经促进了联合 R01 拨款、K01 拨款和两个机构都高度重视博士前/博士后奖学金 - CoHCCC 为我们贡献了超过 80 万美元。 P20 拨款并将每年贡献 25 万美元，以确保 U54 合作伙伴关系的成功，并加强目标 1。 UCR 的癌症研究能力和开发资源以提高 UCR/CoHCCC 联合开发的能力针对我们流域内不同人群的优化治疗剂将提高容量。 UCR 和 CoHCCC 联合开发针对影响不同个体的生存差异的药物目标 3 将为居住在我们南加州社区的人提供培训、机会和指导。确保下一代治疗科学家和临床试验人员反映南方的多样性加利福尼亚州。